{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T19:40:16Z","timestamp":1735414816292,"version":"3.32.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2021 Suzhou High-tech Zone Health Talent Project."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-82575-5","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T04:48:06Z","timestamp":1735361286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database"],"prefix":"10.1038","volume":"14","author":[{"given":"Hong","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiguo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"82575_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris, G. et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann. Oncol. 28, 1260\u20131267 (2017).","journal-title":"Ann. Oncol."},{"key":"82575_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"82575_CR3","first-page":"221","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng, R. S. et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 46, 221\u2013231 (2024).","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"82575_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2015.09.005","volume":"41","author":"C Rojas","year":"2015","unstructured":"Rojas, C. & Slusher, B. S. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant\/palonosetron). Cancer Treat. Rev. 41, 904\u2013913 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"82575_CR5","first-page":"5","volume":"8","author":"DG Frame","year":"2010","unstructured":"Frame, D. G. Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J. Support Oncol. 8, 5\u20139 (2010).","journal-title":"J. Support Oncol."},{"key":"82575_CR6","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.2147\/OTT.S158570","volume":"11","author":"RM Navari","year":"2018","unstructured":"Navari, R. M. & Schwartzberg, L. S. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. Onco Targets Ther. 11, 6459\u20136478 (2018).","journal-title":"Onco Targets Ther."},{"key":"82575_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40265-021-01478-1","volume":"81","author":"M Alam","year":"2021","unstructured":"Alam, M., Buddenkotte, J., Ahmad, F. & Steinhoff, M. Neurokinin 1 receptor antagonists for Pruritus. Drugs 81, 621\u2013634 (2021).","journal-title":"Drugs"},{"key":"82575_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41467-018-07939-8","volume":"10","author":"J Sch\u00f6ppe","year":"2019","unstructured":"Sch\u00f6ppe, J. et al. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists. Nat. Commun. 10, 17 (2019).","journal-title":"Nat. Commun."},{"key":"82575_CR9","first-page":"Cd012775","volume":"11","author":"V Piechotta","year":"2021","unstructured":"Piechotta, V. et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst. Rev. 11, Cd012775 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"82575_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J. Affect. Disord. 346, 223\u2013229 (2024).","journal-title":"J. Affect. Disord"},{"key":"82575_CR11","doi-asserted-by":"publisher","first-page":"103828","DOI":"10.1016\/j.ajp.2023.103828","volume":"90","author":"Q Zhou","year":"2023","unstructured":"Zhou, Q. et al. Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database. Asian J. Psychiatr. 90, 103828 (2023).","journal-title":"Asian J. Psychiatr"},{"key":"82575_CR12","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","volume":"14","author":"F Zou","year":"2023","unstructured":"Zou, F. et al. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front. Pharmacol. 14, 1320458 (2023).","journal-title":"Front. Pharmacol."},{"key":"82575_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40272-023-00613-7","volume":"26","author":"G Wang","year":"2024","unstructured":"Wang, G., Wang, J., Du, R., Wang, Y. & Li, Z. Toxicity spectrum of Anti-GD2 immunotherapy: a real-world study leveraging the US Food and Drug Administration adverse event reporting system. Paediatr. Drugs. 26, 175\u2013185 (2024).","journal-title":"Paediatr. Drugs"},{"key":"82575_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro, M. CINV: still troubling patients after all these years. Support Care Cancer. 26, 5\u20139 (2018).","journal-title":"Support Care Cancer"},{"key":"82575_CR15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/anae.15295","volume":"76","author":"S Weibel","year":"2021","unstructured":"Weibel, S. et al. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta-analysis. Anaesthesia 76, 962\u2013973 (2021).","journal-title":"Anaesthesia"},{"key":"82575_CR16","doi-asserted-by":"publisher","first-page":"e215250","DOI":"10.1001\/jamanetworkopen.2021.5250","volume":"4","author":"DS Wang","year":"2021","unstructured":"Wang, D. S. et al. Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw. Open. 4, e215250 (2021).","journal-title":"JAMA Netw. Open."},{"key":"82575_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","volume":"15","author":"D Osoba","year":"1997","unstructured":"Osoba, D. et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 15, 116\u2013123 (1997).","journal-title":"J. Clin. Oncol."},{"key":"82575_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13045-021-01213-z","volume":"14","author":"L Lin","year":"2021","unstructured":"Lin, L. et al. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990\u20132019. J. Hematol. Oncol. 14, 197 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"82575_CR19","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.1007\/s00520-022-07082-7","volume":"30","author":"G Dranitsaris","year":"2022","unstructured":"Dranitsaris, G., Moezi, M., Dobson, K., Phelan, R. & Blau, S. A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 30, 6649\u20136658 (2022).","journal-title":"Support Care Cancer"},{"key":"82575_CR20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00520-013-2089-8","volume":"22","author":"AD Leal","year":"2014","unstructured":"Leal, A. D. et al. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin\/cyclophosphamide therapy. Support Care Cancer. 22, 1313\u20131317 (2014).","journal-title":"Support Care Cancer"},{"key":"82575_CR21","first-page":"379","volume":"35","author":"T Fujii","year":"2015","unstructured":"Fujii, T. et al. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens. Anticancer Res. 35, 379\u2013383 (2015).","journal-title":"Anticancer Res."},{"key":"82575_CR22","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.21873\/invivo.13704","volume":"38","author":"S Nishibe-Toyosato","year":"2024","unstructured":"Nishibe-Toyosato, S. et al. Comparing injection site reactions of aprepitant and fosaprepitant in gynecologic cancer chemotherapy. Vivo 38, 2374\u20132382 (2024).","journal-title":"Vivo"},{"key":"82575_CR23","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/cpdd.58","volume":"2","author":"J Azuma","year":"2013","unstructured":"Azuma, J. & Fukase, H. Pharmacokinetics of a single 150-mg intravenous infusion of Fosaprepitant: effects of concentration and infusion time in healthy Japanese men. Clin. Pharmacol. Drug Dev. 2, 394\u2013399 (2013).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"82575_CR24","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1177\/1078155218808084","volume":"25","author":"AS Cass","year":"2019","unstructured":"Cass, A. S., Odinet, J. S., Valgus, J. M. & Crona, D. J. Infusion reactions following administration of intravenous rolapitant at an academic medical center. J. Oncol. Pharm. Pract. 25, 1776\u20131783 (2019).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"82575_CR25","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/jcph.966","volume":"57","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Bioequivalence of intravenous and oral rolapitant: results from a randomized, open-label pivotal study. J. Clin. Pharmacol. 57, 1600\u20131606 (2017).","journal-title":"J. Clin. Pharmacol."},{"key":"82575_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3892\/mco.2016.769","volume":"4","author":"T Tsuda","year":"2016","unstructured":"Tsuda, T. et al. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: a retrospective comparison. Mol. Clin. Oncol. 4, 603\u2013606 (2016).","journal-title":"Mol. Clin. Oncol."},{"key":"82575_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1177\/1078155218769347","volume":"25","author":"E Chau","year":"2019","unstructured":"Chau, E., Lundberg, J., Phillips, G., Berger, M. & Wesolowski, R. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. J. Oncol. Pharm. Pract. 25, 1053\u20131057 (2019).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"82575_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1248\/yakushi.22-00186","volume":"143","author":"T Sano","year":"2023","unstructured":"Sano, T., Setsu, N., Kobayashi, E. & Kawai, A. A case of Encephalopathy caused by Drug Interaction between Ifosfamide and Aprepitant. Yakugaku Zasshi. 143, 541\u2013544 (2023).","journal-title":"Yakugaku Zasshi"},{"key":"82575_CR29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00280-019-03949-5","volume":"84","author":"K Shimada","year":"2019","unstructured":"Shimada, K. et al. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration adverse event reporting system and the Japanese adverse drug event report databases. Cancer Chemother. Pharmacol. 84, 1097\u20131105 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"82575_CR30","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/bmt.2010.205","volume":"46","author":"K Jordan","year":"2011","unstructured":"Jordan, K. et al. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transpl. 46, 784\u2013789 (2011).","journal-title":"Bone Marrow Transpl."},{"key":"82575_CR31","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdm104","volume":"18","author":"JP Durand","year":"2007","unstructured":"Durand, J. P., Gourmel, B., Mir, O. & Goldwasser, F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann. Oncol. 18, 808\u2013809 (2007).","journal-title":"Ann. Oncol."},{"key":"82575_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-022-04439-x","volume":"90","author":"F Vazirian","year":"2022","unstructured":"Vazirian, F., Samadi, S., Rahimi, H., Sadeghi, M. & Mohammadpour, A. H. Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. Cancer Chemother. Pharmacol. 90, 1\u20136 (2022).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"82575_CR33","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1177\/1078155220971794","volume":"27","author":"JN Modi","year":"2021","unstructured":"Modi, J. N. & Cimino, S. K. Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant. J. Oncol. Pharm. Pract. 27, 1891\u20131895 (2021).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"82575_CR34","doi-asserted-by":"publisher","first-page":"108366","DOI":"10.1016\/j.pharmthera.2023.108366","volume":"243","author":"JR Idle","year":"2023","unstructured":"Idle, J. R. & Beyo\u011flu, D. Ifosfamide - History, efficacy, toxicity and encephalopathy. Pharmacol. Ther. 243, 108366 (2023).","journal-title":"Pharmacol. Ther."},{"key":"82575_CR35","doi-asserted-by":"crossref","unstructured":"Garcia-Recio, S. & Gasc\u00f3n, P. Biological and Pharmacological aspects of the NK1-Receptor. Biomed. Res. Int. 495704 2015 (2015).","DOI":"10.1155\/2015\/495704"},{"key":"82575_CR36","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1038\/s41467-020-16470-8","volume":"11","author":"J Wils","year":"2020","unstructured":"Wils, J. et al. The neuropeptide substance P regulates aldosterone secretion in human adrenals. Nat. Commun. 11, 2673 (2020).","journal-title":"Nat. Commun."},{"key":"82575_CR37","doi-asserted-by":"crossref","unstructured":"Isorna, I., Esteban, F., Solanellas, J., Cove\u00f1as, R. & Mu\u00f1oz, M. The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study. Eur. J. Histochem. 64, (2020).","DOI":"10.4081\/ejh.2020.3117"},{"key":"82575_CR38","doi-asserted-by":"crossref","unstructured":"Oh, S. Y. et al. Sustained exposure of substance P causes tendinopathy. Int. J. Mol. Sci. 21, (2020).","DOI":"10.3390\/ijms21228633"},{"key":"82575_CR39","doi-asserted-by":"crossref","unstructured":"Ko, K. R. et al. Substance P, a promising therapeutic target in musculoskeletal disorders. Int. J. Mol. Sci. 23, (2022).","DOI":"10.3390\/ijms23052583"},{"key":"82575_CR40","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00726-014-1736-9","volume":"46","author":"M Mu\u00f1oz","year":"2014","unstructured":"Mu\u00f1oz, M. & Cove\u00f1as, R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids. 46, 1727\u20131750 (2014).","journal-title":"Amino Acids"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82575-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82575-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82575-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T19:06:10Z","timestamp":1735412770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82575-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["82575"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-82575-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31201"}}